PMA device
Liposorber(R) LA-15 System Adsorption Column
Kaneka Pharma America Corp. · Lipoprotein, Low Density, Removal (MMY, Class III) · First FDA decision Dec 6, 2000, newest Mar 5, 2025Coronary artery disease
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
15
PMA pathway
Device trials
7
Naming "Liposorber LA-15"
MAUDE reports
43
Brand "Liposorber LA-15", since 2015
PubMed studies
16
Mentioning "Liposorber LA-15"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Liposorber(R) LA-15 System Adsorption Column
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 15 decisions filed under this name.
- LIPOSORBER(R) LA-15 SYSTEM ADSORPTION COLUMN, SULFUX(R) FS-05 PLASMA SEPARATOR, AND TUB. SYST. FOR PLASMAPHER. (LT-MA2).PMA supplement
P910018-S037 · Decided Mar 5, 2025 · 222 days after receipt · Normal 180 Day Track
Device type: Lipoprotein, low density, removal (MMY) · GI, Urology & Nephrology
5 more FDA decisions with a free account
Older decisions: P910018-S021, P910018-S020, P910018-S017, P910018-S015, P910018-S012, P910018-S011, P910018-S007, P910018-S005, P910018-S002
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Liposorber LA-15", any status and sponsor, newest update first.
Kaneka Medical America LLCNot on our public-company list
NCT02235857 · 35 participants (planned) · Start May 3, 2015 · Primary completion Sep 30, 2027
Device: LIPOSORBER® LA-15 System · For: Focal Segmental Glomerulosclerosis
Sites: Loma Linda, California; Los Angeles, California; Wilmington, Delaware · 12 sites in all
6 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Liposorber LA-15", and for the whole product code for context.
This brand
43 reports: 1 malfunction, 38 injury, 4 death
Whole product code MMY
19 reports: 1 malfunction, 16 injury, 2 death
Newest reports for this brand
- LIPOSORBER LA-15 SYSTEMInjury
2435151-2026-00004 · Received Mar 5, 2026
Device type: Apheresis For Focal Glomerulosclerosis In Adult And Pediatric Patients (PBN)
Device problem as coded: Insufficient Device Problem Information
Patient problem as coded: Sepsis; Drug Resistant Bacterial Infection; Bacteremia; Kidney injury
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0900-2022 · Started Feb 17, 2022
Reason given: Labeling change to due to the risk of severe anaphylactoid reactions including shock in patients treated with the Liposorber LA-15 LDL Adsorption Column under concomitant ACE inhibitor medication treatment.
Cause as FDA categorized it: Error in labeling · Device type: Lipoprotein, Low Density, Removal (MMY)
Published research
The most relevant PubMed records for "Liposorber LA-15"[tiab]. The summary above synthesizes these.
- Liposorber® LA-15 system for LDL apheresis in resistant nephrotic syndrome patients.
Al-Mousily M, Nicoara O, Selewski DT, et al. · Pediatr Nephrol · 2022
- An update on LDL apheresis for nephrotic syndrome.
Raina R, Krishnappa V · Pediatr Nephrol · 2019Review
- Low-Density Lipoprotein Adsorption by Centrifugal Plasma Separation Can Shorten Treatment Time.
Ohkubo A, Sakurasawa T, Naito S · Case Rep Nephrol Dial · 2023Case Reports
- LDL-apheresis-induced remission of focal segmental glomerulosclerosis recurrence in pediatric renal transplant recipients.
Shah L, Hooper DK, Okamura D, et al. · Pediatr Nephrol · 2019Multicenter Study
- Dextran-sulfate cellulose adsorption for lowering Lp[a].
Parker TS · Chem Phys Lipids · 1994Clinical Trial, Multicenter Study
- Apheresis technologies for prevention and regression of atherosclerosis: clinical results.
Bambauer R, Schneidewind JM, Latza R · ASAIO J · 1999Clinical Trial, Multicenter Study
- Dextran-Sulfate Plasma Adsorption Lipoprotein Apheresis in Drug Resistant Primary Focal Segmental Glomerulosclerosis Patients: Results From a Prospective, Multicenter, Single-Arm Intervention Study.
Raina R, Krishnappa V, Sanchez-Kazi C, et al. · Front Pediatr · 2019
- Circulating Neurotoxic 5-HT2A Receptor Agonist Autoantibodies in Adult Type 2 Diabetes with Parkinson's Disease.
Zimering MB · J Endocrinol Diabetes · 2018
- Low-density lipoprotein apheresis using the Liposorber dextran sulfate cellulose system for patients with hypercholesterolemia refractory to medical therapy.
Gordon BR, Saal SD · J Clin Apher · 1996Review
- Treatment of refractory familial hypercholesterolemia by low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. The Liposorber Study Group.
Gordon BR, Kelsey SF, Bilheimer DW, et al. · Am J Cardiol · 1992Clinical Trial, Multicenter Study
- Prospective crossover study for a standardized comparison of the dextrane sulfate whole blood and plasma apheresis system in patients with cardiovascular disease and severe dyslipidemia.
Ramlow W, Prophet H, Waitz G · Atheroscler Suppl · 2017Comparative Study, Observational Study
- Low-density lipoprotein apheresis for prevention and regression of atherosclerosis: clinical results.
Bambauer R, Olbricht CJ, Schoeppe E · Ther Apher · 1997Clinical Trial, Comparative Study
Other devices of this type
Also filed under product code MMY.
- H.e.l.p. Plasmat Futura SystemB. Braun Avitum AG · PMA 2015
- Heparin-Induced Extracorporeal Lipoprotein Precipitation (H.e.l.p.) Futura Apheresis SystemB. Braun Avitum AG · PMA 2012
- Blood Tubing System for the Liposorber LA-15 SystemKaneka Pharma America Corp. · PMA 2010
- B.braun,s Heparin-Induced Extracorporeal Lipoprotein Precipitation (H.e.l.p) SystemB. Braun Avitum AG · PMA 2002
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.